The company is pleased to announce the resumption of its activities and drive to commercial production.
Vancouver, B.C., July 30, 2020 – Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSX-V:SVS), The company’s German contractors have reopened to development and commercial production with the German Covid 19 curve successfully flattened. During the slowdown the Company was able to continue to enhance the process, certify equipment and streamline logistics.
The companies unique patented organic algae based product(s) fills an unmet market need in the essential Omega 3 health products market. Sustainable, organic certified and suitable for plant based diets makes the product unique in world. The use of a clean culture system ensures the absence of environmental contaminants often found if ocean based products. Organic is a key differentiator in this multi-billion dollar market.
Solarvest will continue to move our proprietary formulation and process to the German production facilities.
Solarvest BioEnergy Inc. is an algae biotechnology company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein, recombinant viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC proteins to be produced in GMP fermentation facilities.
For further information contact:
Gerri Greenham, Chief Executive Officer
The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.